

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GIANT BIOGENE HOLDING CO., LTD

巨子生物控股有限公司

(An exempted company incorporated in the Cayman Islands with limited liability)

(Stock code: 2367)

PROPOSED CHANGE OF AUDITORS

This announcement is made by Giant Biogene Holding Co., Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

In order to maintain good corporate governance practices, the Company should review auditors engagement arrangement from time to time, which is in the interests of the Company and the shareholders of the Company (the “**Shareholders**”) as a whole. Having considered Ernst & Young (“**EY**”) has audited the consolidated financial statements of the Group for seven consecutive financial years up to and including the year ended 31 December 2025, the board of directors (the “**Board**”) of the Company has reviewed the need for a change of auditors.

The Board announces that, based on the Company’s adherence to sound corporate governance principles, on 30 April 2026, the Board has resolved:

- (1) not to re-appoint the current auditors of the Company, EY, and therefore EY will retire as the auditors of the Company with effect from the conclusion of the forthcoming annual general meeting (the “**AGM**”) of the Company; and
- (2) with the recommendation of the audit committee of the Company (the “**Audit Committee**”), to recommend the appointment of KPMG (“**KPMG**”) as the new auditors of the Company.

The appointment of new auditors will be submitted as an ordinary resolution for approval by the shareholders of the Company (the “**Shareholders**”) in the AGM following the retirement of EY and to hold office until the conclusion of the next annual general meeting of the Company. EY will carry on the audit of the Company for the year ended 31 December 2025 (the “**2025 Audit**”) until the conclusion of the AGM. Therefore, the change of auditors will not have any impact on the 2025 Audit of the Group.

The Board, with the recommendation of the Audit Committee, resolved to propose a resolution at the AGM to approve the appointment of KPMG, Certified Public Accountants in Hong Kong, as the new auditors of the Company, to hold office from the conclusion of the AGM until the conclusion of the next annual general meeting of the Company. Such proposed appointment is subject to the approval of the Shareholders at the AGM.

The Audit Committee has considered a number of factors in assessing the appointment of KPMG as the auditors of the Company, including but not limited to: (i) the scale of the Groups' business; (ii) KPMG's extensive experience, industry knowledge and technical competence in providing audit work to companies listed on the Stock Exchange; (iii) its independence from the Group and objectivity; (iv) its resources and capabilities including but not limited to the size and structure of the audit team; (v) its audit proposal and fee proposal with regard to the scope of audit services required by the Group and the current business size of the Group; and (vi) the relevant guidance issued by the Accounting and Financial Reporting Council ("AFRC"), including Part 2 of the Guidelines for Effective Audit Committees – Selection, Appointment and Reappointment of Auditors published by the AFRC.

Based on the above, the Board and the Audit Committee have assessed and considered KPMG to be eligible and suitable to act as the auditors of the Company. The Board and the Audit Committee are of the view that: (i) by reference to the scale of the Group's business operations and assets, the audit fee agreed with KPMG is commensurate with the scope of audit work required by the Group; (ii) the change of auditors would maintain audit quality and is in the interest of the Company and the Shareholders as a whole; and (iii) KPMG is independent, competent and capable (including manpower, expertise, time and other resources) to perform high quality audit to the Company.

The Company has received a confirmation letter from EY confirming that there are no matters in connection with their retirement as the auditors of the Company upon the conclusion of the AGM that need to be brought to the attention of the Shareholders. The Board and the Audit Committee have also confirmed that there are no disagreements or unresolved matters between the Company and EY or other circumstances in respect of the proposed change of auditors that need to be brought to the attention of the Shareholders.

As at the date of this announcement, EY has not commenced any audit work on the consolidated financial statements of the Group for the financial year ending 31 December 2026. The Board believes that the retirement of EY will not have any significant impact on the annual audit and the release of annual results of the Group for the financial year ending 31 December 2026.

The Board would like to take this opportunity to express its sincere gratitude to EY for their professional services rendered to the Company during the past years.

A circular containing, among other things, further details of the proposed change of auditors and a notice of the AGM will be despatched to the Shareholders in due course.

By Order of the Board
Giant Biogene Holding Co., Ltd
YAN Jianya
Chairman of the Board

Xi'an, the PRC, 30 April 2026

As of the date of this announcement, the Board comprises Mr. Yan Jianya, Ms. Ye Juan, Ms. Fang Juan, Ms. Zhang Huijuan and Ms. Yan Yubo as executive Directors, and Mr. Huang Jin, Mr. Shan Wenhua and Ms. Wong Sze Wing as independent non-executive Directors.